Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shree Ganesh RemediesBOM:540737 -0.05%84 ROE % is 2.75% as of Jun. 2026, which is 87% below its 10-year median of 20.97. GuruFocus rates BOM:540737 with a GF Score™ of 84/100 and a GF Value™ of ₹554.05 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 935 Drug Manufacturers companies, Shree Ganesh Remedies ranks better than 64.28% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shree Ganesh Remedies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Ganesh Remedies ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shree Ganesh Remedies's ROE % distribution charts can be found below:
* The bar in red indicates where Shree Ganesh Remedies's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Shree Ganesh Remedies (BOM:540737) has a ROE % of 2.75% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shree Ganesh Remedies and its competitors. This is 87% below median its historical median of 20.97. Over the past decade, Shree Ganesh Remedies' ROE % has ranged from 10.03 to 26.64. According to the industry distribution chart, Shree Ganesh Remedies ranks #334 out of 935 companies in the Drug Manufacturers industry, placing it in the top 35.7%.
Is Shree Ganesh Remedies' ROE % too high?
Shree Ganesh Remedies' current ROE % of 2.75% is 87% below median its 10-year median of 20.97. Over the past 10 years, this metric has ranged from a low of 10.03 to a high of 26.64. The Drug Manufacturers industry median ROE % is 6.14. Shree Ganesh Remedies' value of 2.75% is 55.2% below this industry median. Based on the distribution chart, Shree Ganesh Remedies ranks #334 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shree Ganesh Remedies has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shree Ganesh Remedies' ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shree Ganesh Remedies ranks #334 out of 935 companies for ROE %. This puts Shree Ganesh Remedies in the upper half of its industry. The industry median ROE % is 6.14. Shree Ganesh Remedies' value of 2.75% is 55.2% below this benchmark. Historically, Shree Ganesh Remedies' own ROE % has ranged from 10.03 to 26.64 over the past decade. While the company's 10-year median is 20.97 vs. the industry median of 6.14, Shree Ganesh Remedies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.14, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shree Ganesh Remedies's current ROE % of 2.75% is 55.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shree Ganesh Remedies and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shree Ganesh Remedies's current ROE % is 2.75%, which is 87% below median its own 10-year median of 20.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shree Ganesh Remedies stock overvalued right now?
Based on GuruFocus' analysis, Shree Ganesh Remedies (BOM:540737) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹554.05, compared to a current price of ₹686.50 — trading 23.9% above its estimated fair value. The current ROE % is 2.75%, which is 87% below median its 10-year median of 20.97 and 55.2% below the Drug Manufacturers industry median of 6.14. Shree Ganesh Remedies' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Shree Ganesh Remedies (BOM:540737), the current ROE % is 2.75% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shree Ganesh Remedies (BOM:540737) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Ganesh Remedies stock appears to be overvalued.
The current stock price of ₹686.50 is trading 23.9% above its estimated GF Value™ of ₹554.05.
GuruFocus considers Shree Ganesh Remedies to be Modestly Overvalued.
Key valuation signals for BOM:540737:
ROE %: 2.75% (87% below median its 10-year median of 20.97)
GF Value™: ₹554.05 vs. price of ₹686.50 (23.9% above fair value)
Industry Position: 55.2% below the Drug Manufacturers median (#334 of 935)
No single metric tells the full story. See the BOM:540737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Ganesh Remedies Ltd manufactures drug intermediates, chemicals, and specialty fine chemicals for the pharmaceutical industry. The company offers pharmaceutical and specialty chemical products, including Trityl chloride, Furoyl chloride, and Dinitolmide. The company's business falls under the primary segment of Bulk Drug Intermediaries.
84GF Score
Get the complete analysis for BOM:540737
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540737 has been successfully added to your 
